ArticleJTCVS open2025
Surgical versus transcatheter aortic valve replacement in patients age <65 years.
Article in JTCVS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcatheter Aortic Valve Replacement in Patients Aged 65 Years and Younger: Unresolved Issues and Future Directions.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: American College of Cardiology/American Heart Association guidelines include a class I indication for surgical aortic valve replacement (SAVR) over transcatheter aortic valve replacement (TAVR) in patients age <65 years. This analysis assessed outcomes of SAVR versus TAVR in patients <65 years. Methods: This was a retrospective, single-institution study of consecutive SAVRs and TAVRs performed between 2013 and 2023. Patients age <65 years were included, and those who underwent concomitant operations or prior AVR were excluded. To balance the AVR cohorts, propensity score matching (PSM) was performed using a 1:1 match ratio. Short-term clinical and echocardiographic outcomes were compared. Kaplan-Meier survival estimation and Fine-Gray analysis of heart failure readmission were performed to evaluate mid-term outcomes after AVR. Results: A total of 761 patients age <65 years underwent AVR, including 655 with SAVR and 106 with isolated TAVR. PSM yielded a cohort of 97 SAVR patients and 97 TAVR patients age <65. After matching, the 2 groups were acceptably balanced across all baseline variables. No significant differences were observed in most immediate postoperative complications. Kaplan-Meier survival estimates were significantly lower for those who underwent TAVR, with 5-year survival rates of 46.3% for TAVR versus 79.7% for SAVR ( Conclusions: TAVR was significantly associated with decreased mid-term survival and increased heart failure readmissions compared to SAVR in patients age <65 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.